{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:35:57Z","timestamp":1789144557017,"version":"build-2803163510"},"reference-count":207,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100016820","name":"Vaccine Research Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016820","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Immunology"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.smim.2020.101428","type":"journal-article","created":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T19:00:01Z","timestamp":1606244401000},"page":"101428","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["Antibody-guided structure-based vaccines"],"prefix":"10.1016","volume":"50","author":[{"given":"Peter D.","family":"Kwong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon J.","family":"DeKosky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey B.","family":"Ulmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5796","key":"10.1016\/j.smim.2020.101428_bib0005","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/289366a0","article-title":"Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution","volume":"289","author":"Wilson","year":"1981","journal-title":"Nature"},{"issue":"6033","key":"10.1016\/j.smim.2020.101428_bib0010","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/317145a0","article-title":"Structure of a human common cold virus and functional relationship to other picornaviruses","volume":"317","author":"Rossmann","year":"1985","journal-title":"Nature"},{"issue":"6686","key":"10.1016\/j.smim.2020.101428_bib0015","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/31405","article-title":"Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody","volume":"393","author":"Kwong","year":"1998","journal-title":"Nature"},{"issue":"5796","key":"10.1016\/j.smim.2020.101428_bib0020","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/289373a0","article-title":"Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation","volume":"289","author":"Wiley","year":"1981","journal-title":"Nature"},{"issue":"6686","key":"10.1016\/j.smim.2020.101428_bib0025","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/31514","article-title":"The antigenic structure of the HIV gp120 envelope glycoprotein","volume":"393","author":"Wyatt","year":"1998","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.smim.2020.101428_bib0030","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/nri891","article-title":"Antibodies, viruses and vaccines","volume":"2","author":"Burton","year":"2002","journal-title":"Nat. Rev. Immunol."},{"issue":"11","key":"10.1016\/j.smim.2020.101428_bib0035","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/nrd1549","article-title":"Docking and scoring in virtual screening for drug discovery: methods and applications","volume":"3","author":"Kitchen","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.smim.2020.101428_bib0040","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/(SICI)1098-1128(199601)16:1<3::AID-MED1>3.0.CO;2-6","article-title":"The art and practice of structure-based drug design: a molecular modeling perspective","volume":"16","author":"Bohacek","year":"1996","journal-title":"Med. Res. Rev."},{"issue":"1","key":"10.1016\/j.smim.2020.101428_bib0045","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1124\/pr.112.007336","article-title":"Computational methods in drug discovery","volume":"66","author":"Sliwoski","year":"2014","journal-title":"Pharmacol. Rev."},{"issue":"7821","key":"10.1016\/j.smim.2020.101428_bib0050","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-020-2571-7","article-title":"Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike","volume":"584","author":"Liu","year":"2020","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.smim.2020.101428_bib0055","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/nm.4512","article-title":"A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite","volume":"24","author":"Kisalu","year":"2018","journal-title":"Nat. Med."},{"issue":"5950","key":"10.1016\/j.smim.2020.101428_bib0060","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1126\/science.1178746","article-title":"Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target","volume":"326","author":"Walker","year":"2009","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.smim.2020.101428_bib0065","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jim.2008.11.012","article-title":"A method for identification of HIV gp140 binding memory B cells in human blood","volume":"343","author":"Scheid","year":"2009","journal-title":"J. Immunol. Methods"},{"issue":"8","key":"10.1016\/j.smim.2020.101428_bib0070","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nm1080","article-title":"An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus","volume":"10","author":"Traggiai","year":"2004","journal-title":"Nat. Med."},{"issue":"6279","key":"10.1016\/j.smim.2020.101428_bib0075","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1126\/science.aad6117","article-title":"Structural and molecular basis for Ebola virus neutralization by protective human antibodies","volume":"351","author":"Misasi","year":"2016","journal-title":"Science"},{"issue":"25","key":"10.1016\/j.smim.2020.101428_bib0080","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1016\/j.vaccine.2014.03.078","article-title":"How advances in immunology provide insight into improving vaccine efficacy","volume":"32","author":"Slifka","year":"2014","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.smim.2020.101428_bib0085","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.4049\/jimmunol.1001155","article-title":"Plasticity and heterogeneity in the generation of memory B cells and long-lived plasma cells: the influence of germinal center interactions and dynamics","volume":"185","author":"Good-Jacobson","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.smim.2020.101428_bib0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.iy.13.040195.000245","article-title":"Choices following antigen entry: antibody formation or immunologic tolerance?","volume":"13","author":"Nossal","year":"1995","journal-title":"Annu. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.smim.2020.101428_bib0095","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.immuni.2018.04.029","article-title":"HIV-1 vaccines based on antibody identification, B cell ontogeny, and epitope structure","volume":"48","author":"Kwong","year":"2018","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.smim.2020.101428_bib0100","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/imr.12505","article-title":"Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies","volume":"275","author":"Verkoczy","year":"2017","journal-title":"Immunol. Rev."},{"issue":"6","key":"10.1016\/j.smim.2020.101428_bib0105","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.cell.2016.08.039","article-title":"Teaching a clone to Walk, one step at a time","volume":"166","author":"Crowe","year":"2016","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.smim.2020.101428_bib0110","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s11248-011-9537-3","article-title":"The construction of transgenic and gene knockout\/knockin mouse models of human disease","volume":"21","author":"Doyle","year":"2012","journal-title":"Transgenic Res."},{"issue":"Suppl 3","key":"10.1016\/j.smim.2020.101428_bib0115","doi-asserted-by":"crossref","first-page":"S246","DOI":"10.1093\/infdis\/jit515","article-title":"Respiratory syncytial virus circulation in seven countries with Global Disease Detection Regional Centers","volume":"208","author":"Haynes","year":"2013","journal-title":"J. Infect. Dis."},{"issue":"3","key":"10.1016\/j.smim.2020.101428_bib0120","first-page":"281","article-title":"Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). I. Isolation, properties and characterization","volume":"66","author":"Chanock","year":"1957","journal-title":"Am. J. Hyg."},{"issue":"2","key":"10.1016\/j.smim.2020.101428_bib0125","doi-asserted-by":"crossref","first-page":"92","DOI":"10.2174\/187152612800100099","article-title":"The burgeoning burden of respiratory syncytial virus among children","volume":"12","author":"Hall","year":"2012","journal-title":"Infect. Disord. Drug Targets"},{"issue":"9725","key":"10.1016\/j.smim.2020.101428_bib0130","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(10)60206-1","article-title":"Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis","volume":"375","author":"Nair","year":"2010","journal-title":"Lancet"},{"issue":"Suppl 2","key":"10.1016\/j.smim.2020.101428_bib0135","doi-asserted-by":"crossref","first-page":"B209","DOI":"10.1016\/j.vaccine.2012.11.106","article-title":"Strategic priorities for respiratory syncytial virus (RSV) vaccine development","volume":"31","author":"Anderson","year":"2013","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.smim.2020.101428_bib0140","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1086\/514115","article-title":"Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus","volume":"176","author":"Johnson","year":"1997","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.smim.2020.101428_bib0145","unstructured":"T. Beaumont, A. Bakker, E. Yasuda, RSV specific binding molecule, Patent US12\/898,325 (2013)."},{"issue":"6136","key":"10.1016\/j.smim.2020.101428_bib0150","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1126\/science.1234914","article-title":"Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody","volume":"340","author":"McLellan","year":"2013","journal-title":"Science"},{"issue":"6158","key":"10.1016\/j.smim.2020.101428_bib0155","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1243283","article-title":"Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus","volume":"342","author":"McLellan","year":"2013","journal-title":"Science"},{"issue":"15","key":"10.1016\/j.smim.2020.101428_bib0160","doi-asserted-by":"crossref","first-page":"7788","DOI":"10.1128\/JVI.00555-11","article-title":"Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes","volume":"85","author":"McLellan","year":"2011","journal-title":"J. Virol."},{"issue":"23","key":"10.1016\/j.smim.2020.101428_bib0165","doi-asserted-by":"crossref","first-page":"9619","DOI":"10.1073\/pnas.1106536108","article-title":"Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers","volume":"108","author":"Swanson","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6452","key":"10.1016\/j.smim.2020.101428_bib0170","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1126\/science.aav9033","article-title":"A proof of concept for structure-based vaccine design targeting RSV in humans","volume":"365","author":"Crank","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.smim.2020.101428_bib0175","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41541-020-0163-z","article-title":"Modified mRNA\/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection","volume":"5","author":"Espeseth","year":"2020","journal-title":"NPJ Vaccines"},{"issue":"23","key":"10.1016\/j.smim.2020.101428_bib0180","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00914-19","article-title":"Alternative virus-like particle-associated prefusion F proteins as maternal vaccines for respiratory syncytial virus","volume":"93","author":"Blanco","year":"2019","journal-title":"J. Virol."},{"issue":"15","key":"10.1016\/j.smim.2020.101428_bib0185","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00189-17","article-title":"Improved prefusion stability, optimized codon usage, and augmented virion packaging enhance the immunogenicity of respiratory syncytial virus fusion protein in a vectored-vaccine candidate","volume":"91","author":"Liang","year":"2017","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.smim.2020.101428_bib0190","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.cell.2019.01.046","article-title":"Induction of potent neutralizing antibody responses by a designed protein nanoparticle vaccine for respiratory syncytial virus","volume":"176","author":"Marcandalli","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.smim.2020.101428_bib0195","doi-asserted-by":"crossref","first-page":"8143","DOI":"10.1038\/ncomms9143","article-title":"A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism","volume":"6","author":"Krarup","year":"2015","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.smim.2020.101428_bib0200","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/infdis\/jiaa193","article-title":"Phase 1 safety and immunogenicity study of a respiratory syncytial virus vaccine with an adenovirus 26 vector encoding prefusion F (Ad26.RSV.preF) in adults aged &\/=60 years","volume":"222","author":"Williams","year":"2020","journal-title":"J. Infect. Dis."},{"issue":"9","key":"10.1016\/j.smim.2020.101428_bib0205","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/nsmb.3267","article-title":"Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV","volume":"23","author":"Joyce","year":"2016","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"2","key":"10.1016\/j.smim.2020.101428_bib0210","article-title":"A single shot pre-fusion-Stabilized bovine RSV F vaccine is safe and effective in Newborn Calves with maternally derived antibodies","volume":"8","author":"Riffault","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.smim.2020.101428_bib0215","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41541-017-0005-9","article-title":"Protection of calves by a prefusion-stabilized bovine RSV F vaccine","volume":"2","author":"Zhang","year":"2017","journal-title":"NPJ Vaccines"},{"issue":"48","key":"10.1016\/j.smim.2020.101428_bib0220","doi-asserted-by":"crossref","first-page":"12265","DOI":"10.1073\/pnas.1811980115","article-title":"Structure-based design of a quadrivalent fusion glycoprotein vaccine for human parainfluenza virus types 1-4","volume":"115","author":"Stewart-Jones","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.smim.2020.101428_bib0225","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nrmicro2548","article-title":"Fusing structure and function: a structural view of the herpesvirus entry machinery","volume":"9","author":"Connolly","year":"2011","journal-title":"Nat. Rev. Microbiol."},{"issue":"8","key":"10.1016\/j.smim.2020.101428_bib0230","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1128\/jvi.62.8.2596-2604.1988","article-title":"Role of glycoprotein B of herpes simplex virus type 1 in viral entry and cell fusion","volume":"62","author":"Cai","year":"1988","journal-title":"J. Virol."},{"issue":"6492","key":"10.1016\/j.smim.2020.101428_bib0235","doi-asserted-by":"crossref","DOI":"10.1126\/science.aay5051","article-title":"De novo protein design enables the precise induction of RSV-neutralizing antibodies","volume":"368","author":"Sesterhenn","year":"2020","journal-title":"Science"},{"issue":"7491","key":"10.1016\/j.smim.2020.101428_bib0240","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nature12966","article-title":"Proof of principle for epitope-focused vaccine design","volume":"507","author":"Correia","year":"2014","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.smim.2020.101428_bib0245","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.jmb.2011.04.044","article-title":"Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus","volume":"409","author":"McLellan","year":"2011","journal-title":"J. Mol. Biol."},{"issue":"2","key":"10.1016\/j.smim.2020.101428_bib0250","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3000164","article-title":"Boosting subdominant neutralizing antibody responses with a computationally designed epitope-focused immunogen","volume":"17","author":"Sesterhenn","year":"2019","journal-title":"PLoS Biol."},{"issue":"24","key":"10.1016\/j.smim.2020.101428_bib0255","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1056\/NEJMoa1208394","article-title":"A phase 3 trial of RTS,S\/AS01 malaria vaccine in African infants","volume":"367","author":"Rts","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.smim.2020.101428_bib0260","article-title":"Vaccines for preventing malaria (SPf66)","author":"Graves","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"issue":"17-18","key":"10.1016\/j.smim.2020.101428_bib0265","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/j.vaccine.2005.01.142","article-title":"Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research","volume":"23","author":"Heppner","year":"2005","journal-title":"Vaccine"},{"issue":"1579","key":"10.1016\/j.smim.2020.101428_bib0270","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1098\/rstb.2011.0091","article-title":"Vaccines against malaria","volume":"366","author":"Hill","year":"2011","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"issue":"5","key":"10.1016\/j.smim.2020.101428_bib0275","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1586\/erv.11.57","article-title":"The R.T.S.,S vaccine candidate for malaria","volume":"10","author":"Regules","year":"2011","journal-title":"Expert Rev. Vaccines"},{"issue":"5","key":"10.1016\/j.smim.2020.101428_bib0280","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/infdis\/jiw237","article-title":"Fractional third and fourth dose of RTS,S\/AS01 malaria candidate vaccine: a phase 2a controlled human malaria parasite infection and immunogenicity study","volume":"214","author":"Regules","year":"2016","journal-title":"J. Infect. Dis."},{"issue":"4","key":"10.1016\/j.smim.2020.101428_bib0285","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.immuni.2020.08.014","article-title":"A Potent Anti-Malarial Human Monoclonal Antibody Targets Circumsporozoite Protein Minor Repeats and Neutralizes Sporozoites in the Liver","volume":"53","author":"Wang","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.smim.2020.101428_bib0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virol.2020.03.003","article-title":"Envelope characteristics in individuals who developed neutralizing antibodies targeting different epitopes in HIV-1 subtype C infection","volume":"546","author":"Ndlovu","year":"2020","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.smim.2020.101428_bib0295","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.str.2018.10.007","article-title":"Structural survey of broadly neutralizing antibodies targeting the HIV-1 env trimer delineates epitope categories and characteristics of recognition","volume":"27","author":"Chuang","year":"2019","journal-title":"Structure"},{"key":"10.1016\/j.smim.2020.101428_bib0300","doi-asserted-by":"crossref","first-page":"16199","DOI":"10.1038\/nmicrobiol.2016.199","article-title":"An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability","volume":"2","author":"van Gils","year":"2016","journal-title":"Nat. Microbiol."},{"issue":"6287","key":"10.1016\/j.smim.2020.101428_bib0305","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1126\/science.aae0474","article-title":"Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody","volume":"352","author":"Kong","year":"2016","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.smim.2020.101428_bib0310","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nsmb.3144","article-title":"Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design","volume":"23","author":"Gorman","year":"2016","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"5","key":"10.1016\/j.smim.2020.101428_bib0315","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.immuni.2015.10.014","article-title":"Identification of common features in prototype broadly neutralizing antibodies to HIV envelope V2 apex to facilitate vaccine design","volume":"43","author":"Andrabi","year":"2015","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.smim.2020.101428_bib0320","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.cell.2015.05.007","article-title":"Structural repertoire of HIV-1-Neutralizing antibodies targeting the CD4 supersite in 14 donors","volume":"161","author":"Zhou","year":"2015","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.smim.2020.101428_bib0325","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0099881","article-title":"Transplanting supersites of HIV-1 vulnerability","volume":"9","author":"Zhou","year":"2014","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.smim.2020.101428_bib0330","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/nsmb.2594","article-title":"Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120","volume":"20","author":"Kong","year":"2013","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"42","key":"10.1016\/j.smim.2020.101428_bib0335","doi-asserted-by":"crossref","first-page":"17880","DOI":"10.1073\/pnas.1004728107","article-title":"Elicitation of structure-specific antibodies by epitope scaffolds","volume":"107","author":"Ofek","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.smim.2020.101428_bib0340","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3000328","article-title":"Star nanoparticles delivering HIV-1 peptide minimal immunogens elicit near-native envelope antibody responses in nonhuman primates","volume":"17","author":"Francica","year":"2019","journal-title":"PLoS Biol."},{"issue":"381","key":"10.1016\/j.smim.2020.101428_bib0345","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aai7521","article-title":"Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide","volume":"9","author":"Alam","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"9","key":"10.1016\/j.smim.2020.101428_bib0350","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1016\/j.celrep.2017.02.003","article-title":"Vaccine elicitation of high mannose-dependent neutralizing antibodies against the V3-Glycan broadly neutralizing epitope in nonhuman Primates","volume":"18","author":"Saunders","year":"2017","journal-title":"Cell Rep."},{"issue":"4","key":"10.1016\/j.smim.2020.101428_bib0355","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0215163","article-title":"Consistent elicitation of cross-clade HIV-neutralizing responses achieved in guinea pigs after fusion peptide priming by repetitive envelope trimer boosting","volume":"14","author":"Cheng","year":"2019","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.smim.2020.101428_bib0360","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/s41591-018-0042-6","article-title":"Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1","volume":"24","author":"Xu","year":"2018","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.smim.2020.101428_bib0365","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.cell.2019.06.030","article-title":"Antibody lineages with vaccine-induced antigen-binding hotspots develop broad HIV neutralization","volume":"178","author":"Kong","year":"2019","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.smim.2020.101428_bib0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107981","article-title":"Immune monitoring reveals fusion peptide priming to imprint cross-clade HIV-Neutralizing responses with a characteristic early B cell signature","volume":"32","author":"Cheng","year":"2020","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.smim.2020.101428_bib0375","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1038\/s41598-020-59711-y","article-title":"Preclinical development of a fusion peptide conjugate as an HIV vaccine immunogen","volume":"10","author":"Ou","year":"2020","journal-title":"Sci. Rep."},{"issue":"5924","key":"10.1016\/j.smim.2020.101428_bib0380","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1126\/science.1171491","article-title":"Antibody recognition of a highly conserved influenza virus epitope","volume":"324","author":"Ekiert","year":"2009","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.smim.2020.101428_bib0385","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nsmb.1566","article-title":"Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses","volume":"16","author":"Sui","year":"2009","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"16","key":"10.1016\/j.smim.2020.101428_bib0390","doi-asserted-by":"crossref","first-page":"5986","DOI":"10.1073\/pnas.0801367105","article-title":"Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies","volume":"105","author":"Kashyap","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.smim.2020.101428_bib0395","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1128\/jvi.68.1.517-520.1994","article-title":"Protection against the mouse-adapted A\/FM\/1\/47 strain of influenza A virus in mice by a monoclonal antibody with cross-neutralizing activity among H1 and H2 strains","volume":"68","author":"Okuno","year":"1994","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.smim.2020.101428_bib0400","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1128\/jvi.67.5.2552-2558.1993","article-title":"A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains","volume":"67","author":"Okuno","year":"1993","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.smim.2020.101428_bib0405","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.cell.2016.06.043","article-title":"Vaccine-induced antibodies that neutralize group 1 and group 2 influenza a viruses","volume":"166","author":"Joyce","year":"2016","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.smim.2020.101428_bib0410","first-page":"2728","article-title":"Passive immunization with influenza haemagglutinin specific monoclonal antibodies","volume":"14","author":"Rudraraju","year":"2018","journal-title":"Hum. Vaccin. Immunother."},{"issue":"Suppl_1","key":"10.1016\/j.smim.2020.101428_bib0415","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1093\/infdis\/jiy711","article-title":"Universal influenza virus vaccines that target the conserved hemagglutinin stalk and conserved sites in the head domain","volume":"219","author":"Krammer","year":"2019","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.smim.2020.101428_bib0420","doi-asserted-by":"crossref","first-page":"22666","DOI":"10.1038\/srep22666","article-title":"Stalking influenza by vaccination with pre-fusion headless HA mini-stem","volume":"6","author":"Valkenburg","year":"2016","journal-title":"Sci. Rep."},{"issue":"6254","key":"10.1016\/j.smim.2020.101428_bib0425","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1126\/science.aac7263","article-title":"A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen","volume":"349","author":"Impagliazzo","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.smim.2020.101428_bib0430","article-title":"Engineered nanoparticle applications for recombinant influenza vaccines","author":"Sia","year":"2020","journal-title":"Mol. Pharm."},{"issue":"8","key":"10.1016\/j.smim.2020.101428_bib0435","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0237218","article-title":"Development of an adjuvanted nanoparticle vaccine against influenza virus, an in vitro study","volume":"15","author":"Rungrojcharoenkit","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.smim.2020.101428_bib0440","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.57659","article-title":"Tailored design of protein nanoparticle scaffolds for multivalent presentation of viral glycoprotein antigens","volume":"9","author":"Ueda","year":"2020","journal-title":"Elife"},{"issue":"5","key":"10.1016\/j.smim.2020.101428_bib0445","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1021\/acsinfecdis.7b00192","article-title":"Two-component ferritin nanoparticles for multimerization of diverse trimeric antigens","volume":"4","author":"Georgiev","year":"2018","journal-title":"ACS Infect. Dis."},{"issue":"7456","key":"10.1016\/j.smim.2020.101428_bib0450","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nature12202","article-title":"Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies","volume":"499","author":"Kanekiyo","year":"2013","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.smim.2020.101428_bib0455","article-title":"Influenza hemagglutinin nanoparticle vaccine elicits broadly neutralizing antibodies against structurally distinct domains of H3N2 HA","volume":"8","author":"Portnoff","year":"2020","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"10.1016\/j.smim.2020.101428_bib0460","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/irv.12697","article-title":"Nanoparticles in influenza subunit vaccine development: immunogenicity enhancement","volume":"14","author":"Khalaj-Hedayati","year":"2020","journal-title":"Influenza Other Respir. Viruses"},{"issue":"9","key":"10.1016\/j.smim.2020.101428_bib0465","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/nm.3927","article-title":"Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection","volume":"21","author":"Yassine","year":"2015","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.smim.2020.101428_bib0470","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S1473-3099(19)30393-7","article-title":"Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial","volume":"20","author":"Bernstein","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.smim.2020.101428_bib0475","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41541-017-0016-6","article-title":"An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial","volume":"2","author":"DeZure","year":"2017","journal-title":"NPJ Vaccines"},{"issue":"13","key":"10.1016\/j.smim.2020.101428_bib0480","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aan2676","article-title":"Preferential induction of cross-group influenza A hemagglutinin stem-specific memory B cells after H7N9 immunization in humans","volume":"2","author":"Andrews","year":"2017","journal-title":"Sci. Immunol."},{"issue":"5956","key":"10.1016\/j.smim.2020.101428_bib0485","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1126\/science.1175868","article-title":"Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120","volume":"326","author":"Chen","year":"2009","journal-title":"Science"},{"issue":"7129","key":"10.1016\/j.smim.2020.101428_bib0490","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/nature05580","article-title":"Structural definition of a conserved neutralization epitope on HIV-1 gp120","volume":"445","author":"Zhou","year":"2007","journal-title":"Nature"},{"issue":"6916","key":"10.1016\/j.smim.2020.101428_bib0495","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nature01188","article-title":"HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites","volume":"420","author":"Kwong","year":"2002","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.smim.2020.101428_bib0500","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/QAD.0000000000000106","article-title":"Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection","volume":"28","author":"Hraber","year":"2014","journal-title":"AIDS"},{"issue":"8","key":"10.1016\/j.smim.2020.101428_bib0505","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1001028","article-title":"A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals","volume":"6","author":"Walker","year":"2010","journal-title":"PLoS Pathog."},{"issue":"14","key":"10.1016\/j.smim.2020.101428_bib0510","doi-asserted-by":"crossref","first-page":"7337","DOI":"10.1128\/JVI.00110-09","article-title":"Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm","volume":"83","author":"Simek","year":"2009","journal-title":"J. Virol."},{"issue":"9","key":"10.1016\/j.smim.2020.101428_bib0515","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/nm1624","article-title":"Broad HIV-1 neutralization mediated by CD4-binding site antibodies","volume":"13","author":"Li","year":"2007","journal-title":"Nat. Med."},{"issue":"5993","key":"10.1016\/j.smim.2020.101428_bib0520","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1126\/science.1192819","article-title":"Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01","volume":"329","author":"Zhou","year":"2010","journal-title":"Science"},{"issue":"5993","key":"10.1016\/j.smim.2020.101428_bib0525","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1126\/science.1187659","article-title":"Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1","volume":"329","author":"Wu","year":"2010","journal-title":"Science"},{"issue":"30","key":"10.1016\/j.smim.2020.101428_bib0530","doi-asserted-by":"crossref","first-page":"E2083","DOI":"10.1073\/pnas.1208984109","article-title":"Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120","volume":"109","author":"West","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.smim.2020.101428_bib0535","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.immuni.2013.04.012","article-title":"Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies","volume":"39","author":"Zhou","year":"2013","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.smim.2020.101428_bib0540","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.cell.2015.03.004","article-title":"Maturation and diversity of the VRC01-Antibody lineage over 15 years of chronic HIV-1 infection","volume":"161","author":"Wu","year":"2015","journal-title":"Cell"},{"issue":"6133","key":"10.1016\/j.smim.2020.101428_bib0545","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1126\/science.1234150","article-title":"Rational HIV immunogen design to target specific germline B cell receptors","volume":"340","author":"Jardine","year":"2013","journal-title":"Science"},{"issue":"6307","key":"10.1016\/j.smim.2020.101428_bib0550","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1126\/science.aah3945","article-title":"Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice","volume":"353","author":"Sok","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.smim.2020.101428_bib0555","doi-asserted-by":"crossref","first-page":"10618","DOI":"10.1038\/ncomms10618","article-title":"Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice","volume":"7","author":"McGuire","year":"2016","journal-title":"Nat. Commun."},{"issue":"6244","key":"10.1016\/j.smim.2020.101428_bib0560","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1126\/science.aac5894","article-title":"HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen","volume":"349","author":"Jardine","year":"2015","journal-title":"Science"},{"issue":"6280","key":"10.1016\/j.smim.2020.101428_bib0565","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1126\/science.aad9195","article-title":"HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen","volume":"351","author":"Jardine","year":"2016","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.smim.2020.101428_bib0570","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.immuni.2018.07.005","article-title":"Glycan masking focuses immune responses to the HIV-1 CD4-Binding site and enhances elicitation of VRC01-Class precursor antibodies","volume":"49","author":"Duan","year":"2018","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.smim.2020.101428_bib0575","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.cell.2016.08.005","article-title":"Tailored immunogens direct affinity maturation toward HIV neutralizing antibodies","volume":"166","author":"Briney","year":"2016","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.smim.2020.101428_bib0580","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.cell.2016.07.029","article-title":"Induction of HIV neutralizing antibody lineages in mice with diverse precursor repertoires","volume":"166","author":"Tian","year":"2016","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.smim.2020.101428_bib0585","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.cell.2016.07.030","article-title":"Sequential immunization elicits broadly neutralizing Anti-HIV-1 antibodies in Ig Knockin Mice","volume":"166","author":"Escolano","year":"2016","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.smim.2020.101428_bib0590","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.immuni.2017.11.023","article-title":"Precursor frequency and affinity determine B cell competitive fitness in germinal centers, tested with germline-targeting HIV vaccine immunogens","volume":"48","author":"Abbott","year":"2018","journal-title":"Immunity"},{"issue":"6470","key":"10.1016\/j.smim.2020.101428_bib0595","doi-asserted-by":"crossref","DOI":"10.1126\/science.aax4380","article-title":"A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses","volume":"366","author":"Steichen","year":"2019","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.smim.2020.101428_bib0600","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1084\/jem.20190446","article-title":"Anti-idiotypic antibodies elicit anti-HIV-1-specific B cell responses","volume":"216","author":"Dosenovic","year":"2019","journal-title":"J. Exp. Med."},{"issue":"10","key":"10.1016\/j.smim.2020.101428_bib0605","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1084\/jem.20190164","article-title":"Detection and activation of HIV broadly neutralizing antibody precursor B cells using anti-idiotypes","volume":"216","author":"Bancroft","year":"2019","journal-title":"J. Exp. Med."},{"issue":"6","key":"10.1016\/j.smim.2020.101428_bib0610","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.3201\/eid2506.181035","article-title":"T. Nigeria lassa fever national response, epidemiologic and clinical features of lassa fever outbreak in Nigeria, January 1-May 6, 2018","volume":"25","author":"Ilori","year":"2019","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.smim.2020.101428_bib0615","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.2147\/DDDT.S147276","article-title":"Current research for a vaccine against Lassa hemorrhagic fever virus","volume":"12","author":"Warner","year":"2018","journal-title":"Drug Des. Devel. Ther."},{"issue":"9","key":"10.1016\/j.smim.2020.101428_bib0620","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1080\/14760584.2016.1184575","article-title":"Vaccine platforms to control Lassa fever","volume":"15","author":"Lukashevich","year":"2016","journal-title":"Expert Rev. Vaccines"},{"issue":"11","key":"10.1016\/j.smim.2020.101428_bib0625","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005276","article-title":"Arenavirus glycan shield promotes neutralizing antibody evasion and protracted infection","volume":"11","author":"Sommerstein","year":"2015","journal-title":"PLoS Pathog."},{"issue":"11","key":"10.1016\/j.smim.2020.101428_bib0630","doi-asserted-by":"crossref","first-page":"5890","DOI":"10.1128\/JVI.01948-08","article-title":"Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys","volume":"83","author":"Baize","year":"2009","journal-title":"J. Virol."},{"issue":"15","key":"10.1016\/j.smim.2020.101428_bib0635","doi-asserted-by":"crossref","first-page":"6777","DOI":"10.1128\/JVI.74.15.6777-6783.2000","article-title":"Effective vaccine for lassa fever","volume":"74","author":"Fisher-Hoch","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.smim.2020.101428_bib0640","doi-asserted-by":"crossref","first-page":"11544","DOI":"10.1038\/ncomms11544","article-title":"Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits","volume":"7","author":"Robinson","year":"2016","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.smim.2020.101428_bib0645","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.cell.2019.07.020","article-title":"Convergent structures illuminate features for germline antibody binding and pan-lassa virus neutralization","volume":"178","author":"Hastie","year":"2019","journal-title":"Cell"},{"issue":"6341","key":"10.1016\/j.smim.2020.101428_bib0650","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1126\/science.aam7260","article-title":"Structural basis for antibody-mediated neutralization of Lassa virus","volume":"356","author":"Hastie","year":"2017","journal-title":"Science"},{"issue":"6507","key":"10.1016\/j.smim.2020.101428_bib0655","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1126\/science.abd2321","article-title":"Structural basis of a shared antibody response to SARS-CoV-2","volume":"369","author":"Yuan","year":"2020","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.smim.2020.101428_bib0660","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.cell.2020.06.025","article-title":"Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies","volume":"182","author":"Barnes","year":"2020","journal-title":"Cell"},{"issue":"7821","key":"10.1016\/j.smim.2020.101428_bib0665","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41586-020-2456-9","article-title":"Convergent antibody responses to SARS-CoV-2 in convalescent individuals","volume":"584","author":"Robbiani","year":"2020","journal-title":"Nature"},{"issue":"6504","key":"10.1016\/j.smim.2020.101428_bib0670","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.abc5902","article-title":"Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability","volume":"369","author":"Brouwer","year":"2020","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.smim.2020.101428_bib0675","doi-asserted-by":"crossref","first-page":"190","DOI":"10.4049\/jimmunol.155.1.190","article-title":"Analysis of the heavy-chain repertoire of human peripheral B-cells using single-cell polymerase chain-reaction","volume":"155","author":"Brezinschek","year":"1995","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.smim.2020.101428_bib0680","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1093\/nar\/22.9.1768","article-title":"PCR amplification of antibody variable regions using primers that anneal to constant regions","volume":"22","author":"Sassano","year":"1994","journal-title":"Nucleic Acids Res."},{"issue":"10","key":"10.1016\/j.smim.2020.101428_bib0685","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nri3285","article-title":"Tools to therapeutically harness the human antibody response","volume":"12","author":"Wilson","year":"2012","journal-title":"Nat. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.smim.2020.101428_bib0690","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.jmb.2006.02.040","article-title":"Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing","volume":"358","author":"Meijer","year":"2006","journal-title":"J. Mol. Biol."},{"issue":"5993","key":"10.1016\/j.smim.2020.101428_bib0695","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1126\/science.1187659","article-title":"Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1","volume":"329","author":"Wu","year":"2010","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.smim.2020.101428_bib0700","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.cell.2015.05.007","article-title":"Structural repertoire of HIV-1-Neutralizing antibodies targeting the CD4 supersite in 14 donors","volume":"161","author":"Zhou","year":"2015","journal-title":"Cell"},{"issue":"6133","key":"10.1016\/j.smim.2020.101428_bib0705","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1126\/science.1234150","article-title":"Rational HIV immunogen design to target specific germline B cell receptors","volume":"340","author":"Jardine","year":"2013","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.smim.2020.101428_bib0710","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1084\/jem.20122824","article-title":"Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies","volume":"210","author":"McGuire","year":"2013","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.smim.2020.101428_bib0715","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.immuni.2018.07.005","article-title":"Glycan masking focuses immune responses to the HIV-1 CD4-Binding site and enhances elicitation of VRC01-Class precursor antibodies","volume":"49","author":"Duan","year":"2018","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.smim.2020.101428_bib0720","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.immuni.2019.06.004","article-title":"Rapid and focused maturation of a VRC01-Class HIV broadly neutralizing antibody lineage involves both binding and accommodation of the N276-Glycan","volume":"51","author":"Umotoy","year":"2019","journal-title":"Immunity"},{"issue":"5928","key":"10.1016\/j.smim.2020.101428_bib0725","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1126\/science.1170020","article-title":"High-throughput sequencing of the zebrafish antibody repertoire","volume":"324","author":"Weinstein","year":"2009","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.smim.2020.101428_bib0730","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/nbt.2782","article-title":"The promise and challenge of high-throughput sequencing of the antibody repertoire","volume":"32","author":"Georgiou","year":"2014","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.smim.2020.101428_bib0735","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4161\/mabs.3.1.14169","article-title":"Sequencing antibody repertoires: the next generation","volume":"3","author":"Fischer","year":"2011","journal-title":"MAbs"},{"issue":"2","key":"10.1016\/j.smim.2020.101428_bib0740","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/eji.201343917","article-title":"Single-cell based high-throughput sequencing of full-length immunoglobulin heavy and light chain genes","volume":"44","author":"Busse","year":"2014","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.smim.2020.101428_bib0745","doi-asserted-by":"crossref","DOI":"10.1002\/art.38754","article-title":"Barcode-enabled sequencing of plasmablast antibody repertoires in rheumatoid arthritis","author":"Tan","year":"2014","journal-title":"Arthritis Rheumatol."},{"issue":"5950","key":"10.1016\/j.smim.2020.101428_bib0750","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1126\/science.1178746","article-title":"Broad and potent neutralizing antibodies from an african donor reveal a new HIV-1 vaccine target","volume":"326","author":"Walker","year":"2009","journal-title":"Science"},{"issue":"7498","key":"10.1016\/j.smim.2020.101428_bib0755","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nature13036","article-title":"Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies","volume":"509","author":"Doria-Rose","year":"2014","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.smim.2020.101428_bib0760","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aaj1879","article-title":"Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors","volume":"1","author":"Gilman","year":"2016","journal-title":"Sci. Immunol."},{"issue":"14","key":"10.1016\/j.smim.2020.101428_bib0765","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aan6809","article-title":"Zika virus activates de novo and cross-reactive memory B cell responses in dengue-experienced donors","volume":"2","author":"Rogers","year":"2017","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.smim.2020.101428_bib0770","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1921388117","article-title":"Longitudinal dynamics of the human B cell response to the yellow fever 17D vaccine","author":"Wec","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"9","key":"10.1016\/j.smim.2020.101428_bib0775","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/nbt.1673","article-title":"Monoclonal antibodies isolated without screening by analyzing the variable-gene repertoire of plasma cells","volume":"28","author":"Reddy","year":"2010","journal-title":"Nat. Biotechnol."},{"issue":"16","key":"10.1016\/j.smim.2020.101428_bib0780","doi-asserted-by":"crossref","first-page":"6470","DOI":"10.1073\/pnas.1219320110","article-title":"Mining the antibodyome for HIV-1-neutralizing antibodies with next-generation sequencing and phylogenetic pairing of heavy\/light chains","volume":"110","author":"Zhu","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"2","key":"10.1016\/j.smim.2020.101428_bib0785","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/nbt.2492","article-title":"High-throughput sequencing of the paired human immunoglobulin heavy and light chain repertoire","volume":"31","author":"DeKosky","year":"2013","journal-title":"Nat. Biotech."},{"issue":"1","key":"10.1016\/j.smim.2020.101428_bib0790","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/nm.3743","article-title":"In-depth determination and analysis of the human paired heavy- and light-chain antibody repertoire","volume":"21","author":"DeKosky","year":"2015","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.smim.2020.101428_bib0795","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/nprot.2016.024","article-title":"Ultra- high-throughput sequencing of the immune receptor repertoire from millions of lymphocytes","volume":"11","author":"McDaniel","year":"2016","journal-title":"Nat. Protoc."},{"issue":"2","key":"10.1016\/j.smim.2020.101428_bib0800","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.jbiosc.2019.01.020","article-title":"Ultrasonically-guided flow focusing generates precise emulsion droplets for high-throughput single cell analyses","volume":"128","author":"Lagerman","year":"2019","journal-title":"J. Biosci. Bioeng."},{"issue":"5","key":"10.1016\/j.smim.2020.101428_bib0805","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.cell.2015.04.044","article-title":"Droplet barcoding for single-cell transcriptomics applied to embryonic stem cells","volume":"161","author":"Klein","year":"2015","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.smim.2020.101428_bib0810","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.cell.2015.05.002","article-title":"Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets","volume":"161","author":"Macosko","year":"2015","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.smim.2020.101428_bib0815","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.molcel.2018.10.020","article-title":"Comparative analysis of droplet-based ultra-high-Throughput single-cell RNA-Seq systems","volume":"73","author":"Zhang","year":"2019","journal-title":"Mol. Cell"},{"issue":"7","key":"10.1016\/j.smim.2020.101428_bib0820","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.cell.2019.11.003","article-title":"High-throughput mapping of B cell receptor sequences to antigen specificity","volume":"179","author":"Setliff","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.smim.2020.101428_bib0825","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41421-020-0168-9","article-title":"Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing","volume":"6","author":"Wen","year":"2020","journal-title":"Cell Discov."},{"key":"10.1016\/j.smim.2020.101428_bib0830","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ymeth.2016.11.006","article-title":"Single cell screening approaches for antibody discovery","volume":"116","author":"Fitzgerald","year":"2017","journal-title":"Methods"},{"key":"10.1016\/j.smim.2020.101428_bib0835","first-page":"1","article-title":"High-throughput single-cell activity-based screening and sequencing of antibodies using droplet microfluidics","author":"G\u00e9rard","year":"2020","journal-title":"Nat. Biotechnol."},{"issue":"10","key":"10.1016\/j.smim.2020.101428_bib0840","doi-asserted-by":"crossref","DOI":"10.1038\/nbt.3964","article-title":"Single-cell deep phenotyping of IgG-secreting cells for high-resolution immune monitoring","volume":"35","author":"Eyer","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.smim.2020.101428_bib0845","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/nbt.4052","article-title":"Functional interrogation and mining of natively paired human VH:VL antibody repertoires","volume":"36","author":"Wang","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.smim.2020.101428_bib0850","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbiotec.2020.06.011","article-title":"The covalent SNAP tag for protein display quantification and Low-pH protein engineering","author":"Jin","year":"2020","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.smim.2020.101428_bib0855","article-title":"Structure-based design with tag-based purification and in-process biotinylation enable streamlined development of SARS-CoV-2 spike molecular probes","author":"Zhou","year":"2020","journal-title":"bioRxiv"},{"issue":"8","key":"10.1016\/j.smim.2020.101428_bib0860","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1073\/pnas.1213737110","article-title":"Molecular deconvolution of the monoclonal antibodies that comprise the polyclonal serum response","volume":"110","author":"Wine","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"6","key":"10.1016\/j.smim.2020.101428_bib0865","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0101322","article-title":"Systematic characterization and comparative analysis of the rabbit immunoglobulin repertoire","volume":"9","author":"Lavinder","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.smim.2020.101428_bib0870","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.celrep.2016.12.013","article-title":"Proteomic analysis of pemphigus autoantibodies indicates a larger, more diverse, and more dynamic repertoire than determined by B cell genetics","volume":"18","author":"Chen","year":"2017","journal-title":"Cell Rep."},{"issue":"6","key":"10.1016\/j.smim.2020.101428_bib0875","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1073\/pnas.1317793111","article-title":"Identification and characterization of the constituent human serum antibodies elicited by vaccination","volume":"111","author":"Lavinder","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"12","key":"10.1016\/j.smim.2020.101428_bib0880","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/nm.4224","article-title":"Molecular-level analysis of the serum antibody repertoire in young adults before and after seasonal influenza vaccination","volume":"22","author":"Lee","year":"2016","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.smim.2020.101428_bib0885","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/nm.4223","article-title":"Influenza immunization elicits antibodies specific for an egg-adapted vaccine strain","volume":"22","author":"Raymond","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.smim.2020.101428_bib0890","first-page":"1","article-title":"Identification of tumor-reactive B cells and systemic IgG in breast cancer based on clonal frequency in the sentinel lymph node","author":"McDaniel","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"issue":"3","key":"10.1016\/j.smim.2020.101428_bib0895","doi-asserted-by":"crossref","DOI":"10.1016\/j.chom.2019.01.010","article-title":"Persistent antibody clonotypes dominate the serum response to influenza over multiple years and repeated vaccinations","volume":"25","author":"Lee","year":"2019","journal-title":"Cell Host Microbe"},{"issue":"7","key":"10.1016\/j.smim.2020.101428_bib0900","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aal2200","article-title":"Potent and broad HIV-neutralizing antibodies in memory B cells and plasma","volume":"2","author":"Williams","year":"2017","journal-title":"Sci. Immunol."},{"issue":"6","key":"10.1016\/j.smim.2020.101428_bib0905","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.4049\/jimmunol.179.6.3841","article-title":"Kinetic, affinity, and diversity limits of human polyclonal antibody responses against tetanus toxoid","volume":"179","author":"Poulsen","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.smim.2020.101428_bib0910","series-title":"Review, Synthesis, and Application of Information on the Human Lymphatic System to Radiation Dosimetry for Chronic Lymphocytic Leukemia","author":"Apostoaei","year":"2012"},{"issue":"9","key":"10.1016\/j.smim.2020.101428_bib0915","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.celrep.2016.10.085","article-title":"Direct probing of germinal center responses reveals immunological features and bottlenecks for neutralizing antibody responses to HIV env trimer","volume":"17","author":"Havenar-Daughton","year":"2016","journal-title":"Cell Rep."},{"issue":"8","key":"10.1016\/j.smim.2020.101428_bib0920","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/nm.1974","article-title":"Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques","volume":"15","author":"Hessell","year":"2009","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.smim.2020.101428_bib0925","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1086\/600891","article-title":"Power to detect the effects of HIV vaccination in repeated low-dose challenge experiments","volume":"200","author":"Hudgens","year":"2009","journal-title":"J. Infect. Dis."},{"issue":"4","key":"10.1016\/j.smim.2020.101428_bib0930","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/j.1541-0420.2009.01189.x","article-title":"Assessing vaccine effects in repeated low-dose challenge experiments","volume":"65","author":"Hudgens","year":"2009","journal-title":"Biometrics"},{"issue":"6","key":"10.1016\/j.smim.2020.101428_bib0935","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.cell.2016.07.029","article-title":"Induction of HIV neutralizing antibody lineages in mice with diverse precursor repertoires","volume":"166","author":"Tian","year":"2016","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.smim.2020.101428_bib0940","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.cell.2015.06.003","article-title":"Immunization for HIV-1 broadly neutralizing antibodies in human ig knockin mice","volume":"161","author":"Dosenovic","year":"2015","journal-title":"Cell"},{"issue":"18","key":"10.1016\/j.smim.2020.101428_bib0945","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1073\/pnas.1803457115","article-title":"Anti\u2013HIV-1 B cell responses are dependent on B cell precursor frequency and antigen-binding affinity","volume":"115","author":"Dosenovic","year":"2018","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"2","key":"10.1016\/j.smim.2020.101428_bib0950","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.immuni.2017.07.009","article-title":"Fc\u03b3 receptor function and the design of vaccination strategies","volume":"47","author":"Bournazos","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.smim.2020.101428_bib0955","series-title":"Fc Receptors","first-page":"237","article-title":"Humanized mice to study Fc\u03b3R function","author":"Bournazos","year":"2014"},{"issue":"6","key":"10.1016\/j.smim.2020.101428_bib0960","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/s41591-018-0042-6","article-title":"Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1","volume":"24","author":"Xu","year":"2018","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.smim.2020.101428_bib0965","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0215163","article-title":"Consistent elicitation of cross-clade HIV-neutralizing responses achieved in guinea pigs after fusion peptide priming by repetitive envelope trimer boosting","volume":"14","author":"Cheng","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.smim.2020.101428_bib0970","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00074-20","article-title":"Development of a 3Mut-Apex-Stabilized envelope trimer that expands HIV-1 neutralization breadth when used to boost fusion peptide-directed vaccine-elicited responses","author":"Chuang","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.smim.2020.101428_bib0975","doi-asserted-by":"crossref","first-page":"19570","DOI":"10.1038\/srep19570","article-title":"Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens","volume":"6","author":"Knudsen","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.smim.2020.101428_bib0980","series-title":"Vaccine Adjuvants","first-page":"353","article-title":"Molecular methods and bioinformatic tools for adjuvant characterization by high-throughput sequencing","author":"Wiley","year":"2017"},{"issue":"7","key":"10.1016\/j.smim.2020.101428_bib0985","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nri3694","article-title":"From empiricism to rational design: a personal perspective of the evolution of vaccine development","volume":"14","author":"De Gregorio","year":"2014","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.smim.2020.101428_bib0990","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1586\/14760584.2014.907528","article-title":"Physicochemical and functional characterization of vaccine antigens and adjuvants","volume":"13","author":"Dey","year":"2014","journal-title":"Expert Rev. Vaccines"},{"issue":"5","key":"10.1016\/j.smim.2020.101428_bib0995","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41587-020-0507-2","article-title":"Viral contamination in biologic manufacture and implications for emerging therapies","volume":"38","author":"Barone","year":"2020","journal-title":"Nat. Biotechnol."},{"issue":"3","key":"10.1016\/j.smim.2020.101428_bib1000","article-title":"Moving from empirical to rational vaccine design in the\u2019 Omics\u2019 era","volume":"7","author":"Sharma","year":"2019","journal-title":"Vaccines (Basel)"},{"issue":"4","key":"10.1016\/j.smim.2020.101428_bib1005","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a031583","article-title":"What is the predictive value of animal models for vaccine efficacy in humans? Consideration of strategies to improve the value of animal models","volume":"10","author":"Herati","year":"2018","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"1","key":"10.1016\/j.smim.2020.101428_bib1010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.cji.0000211341.88835.ae","article-title":"G. Cancer Vaccine Clinical Trial Working, A clinical development paradigm for cancer vaccines and related biologics","volume":"30","author":"Hoos","year":"2007","journal-title":"J. Immunother."},{"issue":"6","key":"10.1016\/j.smim.2020.101428_bib1015","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.vaccine.2018.12.040","article-title":"Demonstrating vaccine effectiveness during a waning epidemic: a WHO\/NIH meeting report on approaches to development and licensure of Zika vaccine candidates","volume":"37","author":"Vannice","year":"2019","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.smim.2020.101428_bib1020","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12916-018-1017-7","article-title":"Adaptive designs in clinical trials: why use them, and how to run and report them","volume":"16","author":"Pallmann","year":"2018","journal-title":"BMC Med."},{"key":"10.1016\/j.smim.2020.101428_bib1025","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.biologicals.2018.02.002","article-title":"m. Session chairs at the second Human Challenge Trials, Human challenge trials in vaccine development, Rockville, MD, USA, September 28-30, 2017","volume":"61","author":"Baay","year":"2019","journal-title":"Biologicals"},{"issue":"11\u201312","key":"10.1016\/j.smim.2020.101428_bib1030","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.micinf.2018.03.001","article-title":"Rapid response to an emerging infectious disease - Lessons learned from development of a synthetic DNA vaccine targeting Zika virus","volume":"20","author":"Kudchodkar","year":"2018","journal-title":"Microbes Infect."},{"key":"10.1016\/j.smim.2020.101428_bib1035","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","author":"Corbett","year":"2020","journal-title":"Nature"}],"container-title":["Seminars in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532320300440?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532320300440?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T23:21:18Z","timestamp":1760916078000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044532320300440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":207,"alternative-id":["S1044532320300440"],"URL":"https:\/\/doi.org\/10.1016\/j.smim.2020.101428","relation":{},"ISSN":["1044-5323"],"issn-type":[{"value":"1044-5323","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody-guided structure-based vaccines","name":"articletitle","label":"Article Title"},{"value":"Seminars in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.smim.2020.101428","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101428"}}